Since the intra-tumor heterogeneity of HCC and potential complications brought by liver biopsy, our clinical prediction tool identified GPC3 status satisfactorily and might be helpful in clinical decision-making. This evidence concerns the gene GPC3 and hepatocellular carcinoma.